Anticancer potential of osthole: targeting gynecological tumors and breast cancer

被引:0
作者
Han, Yingqi [1 ]
Sun, Zhengao [2 ]
机构
[1] Shandong Univ Tradit Chinese Med, Clin Coll 1, Jingshi Rd 16369, Jinan 250014, Peoples R China
[2] Shandong Univ Tradit Chinese Med, Dept Reprod & Genet, Affiliated Hosp, 42 Wenhua West Rd, Jinan 250014, Shangdong Provi, Peoples R China
关键词
Osthole; Gynecological tumors; Breast cancer; Chinese herbal medicine; Mechanism; CELL-PROLIFERATION; OVARIAN-CANCER; EXPRESSION; PHARMACOKINETICS; APOPTOSIS; INVASION; THERAPY; PATHWAY; RATS;
D O I
10.1007/s43440-024-00685-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Gynecological tumors, such as ovarian, endometrial, and cervical cancers, alongside breast cancer, represent significant malignancies that pose serious threats to women's health worldwide. Standard treatments, including surgery, chemotherapy, radiotherapy, and targeted therapies, are commonly utilized in clinical practice. However, challenges such as high recurrence rates, drug resistance, and adverse side effects underscore the urgent need for more effective therapeutic options. Osthole, a natural coumarin compound derived from Chinese herbal medicine, has demonstrated remarkable antitumor activity against various cancers. Emerging evidence indicates that osthole can inhibit the proliferation, invasion, and metastasis of gynecological and breast cancer cells through various mechanisms, including inducing apoptosis and autophagy, regulating the tumor microenvironment, inhibiting tumor angiogenesis, and enhancing the sensitivity of cancer cells to chemotherapy and radiotherapy. This review highlights the recent advancements in osthole research within the context of gynecological and breast cancers, focusing on its molecular mechanisms, and offers a theoretical foundation for its potential development as an anticancer agent.
引用
收藏
页码:87 / 102
页数:16
相关论文
共 116 条
  • [1] Cervical Cancer, Version 1.2024 Featured Updates to the NCCN Guidelines
    Abu-Rustum, Nadeem R.
    Yashar, Catheryn M.
    Arend, Rebecca
    Barber, Emma
    Bradley, Kristin
    Brooks, Rebecca
    Campos, Susana M.
    Chino, Junzo
    Chon, Hye Sook
    Crispens, Marta Ann
    Damast, Shari
    Fisher, Christine M.
    Frederick, Peter
    Gaffney, David K.
    Gaillard, Stephanie
    Giuntoli, Robert
    Glaser, Scott
    Holmes, Jordan
    Howitt, Brooke E.
    Lea, Jayanthi
    Mantia-Smaldone, Gina
    Mariani, Andrea
    Mutch, David
    Nagel, Christa
    Nekhlyudov, Larissa
    Podoll, Mirna
    Rodabaugh, Kerry
    Salani, Ritu
    Schorge, John
    Siedel, Jean
    Sisodia, Rachel
    Soliman, Pamela
    Ueda, Stefanie
    Urban, Renata
    Wyse, Emily
    McMillian, Nicole R.
    Aggarwal, Shaili
    Espinosa, Sara
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2023, 21 (12): : 1225 - 1233
  • [2] Armstrong Deborah K, 2022, J Natl Compr Canc Netw, V20, P972, DOI 10.6004/jnccn.2022.0047
  • [3] Osthole interacts with an ER-mitochondria axis and facilitates tumor suppression in ovarian cancer
    Bae, Hyocheol
    Lee, Jin-Young
    Song, Jisoo
    Song, Gwonhwa
    Lim, Whasun
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 2021, 236 (02) : 1025 - 1042
  • [4] Breast cancer: Biology, biomarkers, and treatments
    Barzaman, Khadijeh
    Karami, Jafar
    Zarei, Zeinab
    Hosseinzadeh, Aysooda
    Kazemi, Mohammad Hossein
    Moradi-Kalbolandi, Shima
    Safari, Elahe
    Farahmand, Leila
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 84
  • [5] Cellular landscaping of cisplatin resistance in cervical cancer
    Bhattacharjee, Rahul
    Dey, Tanima
    Kumar, Lamha
    Kar, Sulagna
    Sarkar, Ritayan
    Ghorai, Mimosa
    Malik, Sumira
    Jha, Niraj Kumar
    Vellingiri, Balachandar
    Kesari, Kavindra Kumar
    de la Lastra, Jose M. Perez
    Dey, Abhijit
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2022, 153
  • [6] Anticancer Potential of Coumarin and its Derivatives
    Bhattarai, Narayan
    Kumbhar, Anupa A.
    Pokharel, Yuba Raj
    Yadav, Paras Nath
    [J]. MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2021, 21 (19) : 2996 - 3029
  • [7] TMEM25 inhibits monomeric EGFR-mediated STAT3 activation in basal state to suppress triple-negative breast cancer progression
    Bi, Jing
    Wu, Zhihui
    Zhang, Xin
    Zeng, Taoling
    Dai, Wanjun
    Qiu, Ningyuan
    Xu, Mingfeng
    Qiao, Yikai
    Ke, Lang
    Zhao, Jiayi
    Cao, Xinyu
    Lin, Qi
    Chen, Xiao Lei
    Xie, Liping
    Ouyang, Zhong
    Guo, Jujiang
    Zheng, Liangkai
    Ma, Chao
    Guo, Shiying
    Chen, Kangmei
    Mo, Wei
    Fu, Guo
    Zhao, Tong-Jin
    Wang, Hong-Rui
    [J]. NATURE COMMUNICATIONS, 2023, 14 (01)
  • [8] Endothelium and cancer metastasis: Perspectives for antimetastatic therapy
    Blazejczyk, Agnieszka
    Papiernik, Diana
    Porshneva, Kseniia
    Sadowska, Joanna
    Wietrzyk, Joanna
    [J]. PHARMACOLOGICAL REPORTS, 2015, 67 (04) : 711 - 718
  • [9] Human papillomavirus and cervical cancer
    Burd, EM
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 2003, 16 (01) : 1 - +
  • [10] Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
    Burstein, H. J.
    Curigliano, G.
    Loibl, S.
    Dubsky, P.
    Gnant, M.
    Poortmans, P.
    Colleoni, M.
    Denkert, C.
    Piccart-Gebhart, M.
    Regan, M.
    Senn, H. -J.
    Winer, E. P.
    Thurlimann, B.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (10) : 1541 - 1557